Current Cardiovascular Risk Reports

, Volume 5, Issue 1, pp 38–44

Beyond Cholesterol in the Primary Prevention of Cardiovascular Disease: Is The Polypill the Answer?

Article

Abstract

In spite of major advances in the diagnosis and treatment of cardiovascular diseases, they remain the primary cause of death worldwide. Furthermore, the burden of disease is increasing steadily, particularly in emerging countries. Inappropriate prescription, unaffordable cost of medication, and lack of adherence to treatment all contribute to the failure of cardiovascular prevention. In addition, identification of patients at high risk of new ischemic events by means of the available scores is relatively inefficient, as most events occur in individuals with only modest elevations of risk factors. The concept of a fixed-dose combination or “polypill” has emerged recently as a potential strategy for improving cardiovascular disease burden. It is argued that such an approach will make unnecessary patient identification while reducing cost and improving adherence to medication. Several polypills are being developed and some of them are undergoing clinical testing.

Keywords

Polypill Cardiovascular prevention Primary prevention Statins 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Sanz J, Moreno PR, Fuster V. Update on advances in atherothrombosis. Nat Clin Pract Cardiovasc Med. 2007;4(2):78–89.CrossRefPubMedGoogle Scholar
  2. 2.
    Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Beaglehole R, Reddy S, Leeder SR. Poverty and human development: the global implications of cardiovascular disease. Circulation. 2007;116(17):1871–3.CrossRefPubMedGoogle Scholar
  4. 4.
    Cooney MT, Dudina A, Whincup P, Capewell S, Menotti A, Jousilahti P, Njølstad I, Oganov R, Thomsen T, Tverdal A, Wedel H, Wilhelmsen L, Graham I; SCORE Investigators. Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil. 2009;16(5):541–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Fletcher GF, Bufalino V, Costa F, et al. Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. Am J Cardiol 2007;99:1E-35E.CrossRefPubMedGoogle Scholar
  6. 6.
    Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78CrossRefPubMedGoogle Scholar
  7. 7.
    Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948–54.CrossRefPubMedGoogle Scholar
  9. 9.
    Davies AR, Smeeth L, Grundy EM. Contribution of changes in incidence and mortality to trends in the prevalence of coronary heart disease in the UK: 1996 2005. Eur Heart J. 2007;28(17):2142–7..CrossRefPubMedGoogle Scholar
  10. 10.
    WHO report. Preventing chronic disease. Available at http://www.who.int/chp/chronic_disease_report Accessed September 2010
  11. 11.
    Daar AS, Singer PA, Persad DL, Pramming SK, Matthews DR, Beaglehole R, et al. Grand challenges in chronic non-communicable diseases. Nature. 2007;450(7169):494–6.CrossRefPubMedGoogle Scholar
  12. 12.
    •• Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 Mar 14;373(9667):929–40. This third European survey provides a clear view of secondary prevention in 22 countries in Europe. CrossRefPubMedGoogle Scholar
  13. 13.
    Mendis S. WHO Study on prevention of recurrences of myocardial infarction and stroke (WHO-PREMISE). Bulletin of WHO 2005;83:820–8.Google Scholar
  14. 14.
    Mendis S, Fukino K, Cameron A, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ 2007;85:279–88.CrossRefPubMedGoogle Scholar
  15. 15.
    Pharma 2020: the vision. Which path will you take? Available at http://www.pwc.com/pharma. Accessed September 2010.
  16. 16.
    Bosworth HB. Medication treatment adherence. Chapter 6, 147–94. In: Bosworth H, Oddone, E., Weinberger, M., ed. In: “Patient treatment adherence”. Mahwah, New Jersey 2006.Google Scholar
  17. 17.
    Cutler DM, Everett W. Thinking outside the pillbox—medication adherence as a priority for health care reform. N Engl J Med. 2010;362(17):1553–5. Epub 2010 Apr 7.CrossRefPubMedGoogle Scholar
  18. 18.
    • Ho PM, Bryson CL, Rumsfeld JS. Medication Adherence. Its importance in cardiovascular outcomes. Circulation. 2009; 119:3028–3035 These authors summarize the present evidence on the importance of treatment adherence in the outcome of patients with chronic cardiac conditions. CrossRefPubMedGoogle Scholar
  19. 19.
    Jansà M, Hernández C, Vidal M, Nuñez M, Bertran MJ, Sanz S, et al. Multidimensional analysis of treatment adherence in patients with multiple chronic conditions. A cross-sectional study in a tertiary hospital. Patient Educ Couns. 2010 Feb 16Google Scholar
  20. 20.
    Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008;117:1028–36.CrossRefPubMedGoogle Scholar
  22. 22.
    • Bramlage P, Messer C, Bitterlich N, Pohlmann C, Cuneo A, Stammwitz E, Tebbenjohanns J, Gohlke H, Senges J, Tebbe U. The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart. 2010;96(8):604–9. The MITRA registry is an important piece of information regarding the role of secondary prevention in post-MI patients. CrossRefPubMedGoogle Scholar
  23. 23.
    Danchin N, Cambou JP, Hanania G, et al. Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. Am Heart J 2005;150:1147–53.CrossRefPubMedGoogle Scholar
  24. 24.
    •• Lonn E, Yusuf S. Polypill: the evidence and the promise. Curr Opin Lipidol. 2009;20:453–9. One of the most active groups discusses the polypill strategy following the TIPS study. CrossRefPubMedGoogle Scholar
  25. 25.
    Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.CrossRefPubMedGoogle Scholar
  26. 26.
    Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.CrossRefPubMedGoogle Scholar
  27. 27.
    Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.CrossRefPubMedGoogle Scholar
  28. 28.
    UMPIRE. Use of a mltidrug pill in reducing cardiovascular events. Available at http://clinicaltrials.gov. Accessed September 2010
  29. 29.
    •• Wald NJ, Wald DS. The polypill concept. Heart. 2010 Jan;96(1):1–4. A recent reappraisal of the polypill concept by one of the authors that pioneered the concept.CrossRefPubMedGoogle Scholar
  30. 30.
    Wald NJ, Wald DS. The polypill concept. Postgrad Med J. 2010 May;86(1015):257–60.CrossRefPubMedGoogle Scholar
  31. 31.
    Wald DS, Wald NJ. The polypill in the primary prevention of cardiovascular disease. Fundam Clin Pharmacol. 2010;24(1):29–35. Epub 2009 Nov 23.CrossRefPubMedGoogle Scholar
  32. 32.
    Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registerability of the polypill. Eur Heart J 2006;27:1651–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Reddy S. The prevetive polypill. Much promise, insufficient evidence. New England Journal of Medicine 2007 2007:212.CrossRefGoogle Scholar
  34. 34.
    Teo KK, Liang Y. Polypill: lights and shadows. Curr Hypertens Rep. 2010;12(4):276–81.CrossRefPubMedGoogle Scholar
  35. 35.
    Elley CR, Toop L. A polypill is the solution to the pharmacological management of cardiovascular risk. J Prim Health Care. 2009 Sep;1(3):232–6.PubMedGoogle Scholar
  36. 36.
    Wierzbicki AS, Minhas R. The poly-pill: does it work and is chronic therapy acceptable? Int J Clin Pract. 2010;64(9):1171–3.CrossRefPubMedGoogle Scholar
  37. 37.
    Spence JD. Polypill: for Pollyanna. Int J Stroke. 2008 May;3(2):92–7.CrossRefPubMedGoogle Scholar
  38. 38.
    •• Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373(9672):1341–51. Epub 2009 Mar 30. This is the first large study analyzing the polypill in the clinical arena.CrossRefPubMedGoogle Scholar
  39. 39.
    Patel A, Shah T, Shah G, Jha V, Ghosh C, Desai J, Khamar B, Chakraborty BS. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. Am J Cardiovasc Drugs. 2010;10(2):95–103CrossRefPubMedGoogle Scholar
  40. 40.
    Guglietta A, Guerrero M. Issues to consider in the pharmaceutical development of a cardiovascular polypill. Nat Clin Pract Cardiovasc Med. 2009;6:112–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Forslund L. Reflections on the regulation of the Polypill. Nat Clin Pract Cardiovasc Med. 2009;6(2):94–5. Epub 2008 Dec 2.CrossRefPubMedGoogle Scholar
  42. 42.
    Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med. 2009;6:101–10.CrossRefPubMedGoogle Scholar
  43. 43.
    Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, Nateghi A, Rastegarpanah M, Khoshnia M, Semnani S, Salahi R, Thomas GN, Larijani B, Cheng KK, Malekzadeh R. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors. Int J Clin Pract. 2010 Aug;64(9):1220–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Translational Cardiovascular ResearchNational Center for Cardiovascular Research (CNIC)MadridSpain

Personalised recommendations